You are using an unsupported browser. Please use the latest version of Chrome, Firefox, Safari or Edge.
The one hundred honoree: Shannon Himber

Profile in Medicine

The one hundred honoree: Shannon Himber

by
Mass General Giving

Shannon Himber’s professionalism, expertise and positive spirit all play a pivotal role in the continued success of the Mass General Cancer Center Protocol Office.

Shannon is “a phenomenal individual, smart, sharp, efficient, effective, pleasant, fun, and easily approachable,” says Helen Shih, MD, associate medical director of the Francis H. Burr Proton Therapy Center. “Shannon has always held herself and others to the highest level of integrity and performance,” adds Jeffrey Clark, MD, director of Clinical Trials Support. Even more well-deserved praise comes from Glenn Siegmann, MS, RPh, administrative director of the Protocol Office. “Shannon is the consummate professional.”

These colleagues, and many more, understand the significant impact that Shannon has as an associate director of the Cancer Center Protocol Office. Clinical trials are essential to research efforts to improve treatments for patients with cancer. Shannon is instrumental to this process, managing multiple aspects of the clinical research efforts within the Mass General Cancer Center. She oversees the Education and Training program, Multi-Center Group, enrollment monitors, and the group overseeing Regulatory Affairs, in addition to overseeing the managers of the GI, Sarcoma, Leukemia, BMT and the Proton Center programs.

Highly respected by her peers from both Mass General and the Dana-Farber Cancer Institute, Shannon refuses to accept the status quo and is constantly looking for ways to go above and beyond. “She’s gone out of her way to find out more information about each of the clinical research areas,” says Dr. Clark. “Shannon’s not shy about asking questions and persisting until there has been a satisfactory answer and solution. Without a doubt, she’s been pivotal in significantly improving the conduct of clinical trials.”